Damon Biotech
Executive Summary
Company says it has received $500,000 in new orders from "two biotech companies" for contract production of certain anti-cancer monoclonal antibodies. One is scheduled for Phase III testing while another, originally developed at the National Cancer Institute, will be tested against colon and breat cancer.